SPRY Graph | ARS Pharmaceuticals, Inc.

SPRY Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $33.66M; Research and development $4.70M; Selling, general and administrative $77.58M; Operating expenses $95.12M.
2026-03-31: Revenue $22.68M; Research and development $4.34M; Selling, general and administrative $72.20M; Operating expenses $82.83M.
2025-12-31: Revenue $28.09M*; Research and development $3.44M*; Selling, general and administrative $59.95M*; Operating expenses $69.55M*.
2025-09-30: Revenue $32.50M; Research and development $2.75M; Selling, general and administrative $74.75M; Operating expenses $85.69M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Selling, general and administrative	Operating expenses	Net income
2026-06-30	$33.66M	$4.70M	$77.58M	$95.12M	-$62.34M
2026-03-31	$22.68M	$4.34M	$72.20M	$82.83M	-$60.62M
2025-12-31	$28.09M*	$3.44M*	$59.95M*	$69.55M*	-$41.32M*
2025-09-30	$32.50M	$2.75M	$74.75M	$85.69M	-$51.15M
2025-06-30	$15.72M	$4.04M	$54.31M	$63.33M	-$44.88M
2025-03-31	$7.97M	$2.95M	$41.10M	$45.15M	-$33.94M
2024-09-30	$2.07M	$4.42M	$19.28M	$23.82M	-$19.13M
2024-06-30	$500.00K	$6.90M	$8.94M	$15.84M	-$12.52M
2024-03-31	$0.00	$5.23M	$7.96M	$13.19M	-$10.29M
2023-09-30	$0.00	$3.00M	$14.98M	$17.98M	-$14.87M
2023-06-30	$10.00K	$7.31M	$181.00K	$20.61M	-$17.37M
2023-03-31	$20.00K	$6.55M	$337.00K	$18.73M	-$14.96M
2022-09-30	$189.00K	$3.89M	(m)	$6.82M	-$6.58M
2022-06-30	$464.00K	$4.35M	(m)	$6.81M	-$6.42M
2022-03-31	$663.00K	$5.42M	(m)	$7.76M	-$7.25M
2021-09-30	(m)	$15.64M	(m)	$22.68M	-$22.66M
2021-06-30	(m)	$17.75M	(m)	$24.51M	-$24.50M
2021-03-31	(m)	$12.24M	(m)	$18.89M	-$18.87M
2020-09-30	(m)	$6.20M	(m)	$8.11M	-$8.12M
2020-06-30	(m)	$5.13M	(m)	$6.46M	-$6.47M
2020-03-31	(m)	$4.41M	(m)	$5.24M	-$5.28M

Revenue and expense 6 month

Period end	Revenue	Research and development	Selling, general and administrative	Operating expenses	Net income
2026-06-30	$56.34M	$9.03M	$149.78M	$177.95M	-$122.96M
2025-06-30	$23.69M	$6.99M	$95.42M	$108.48M	-$78.82M
2024-06-30	$500.00K	$12.13M	$16.90M	$29.03M	-$22.81M
2023-06-30	$30.00K	$13.86M	$518.00K	$39.35M	-$32.33M
2022-06-30	$1.13M	$9.77M	(m)	$14.57M	-$13.67M
2021-06-30	(m)	$29.99M	(m)	$43.40M	-$43.36M
2020-06-30	(m)	$9.54M	(m)	$11.71M	-$11.75M

Revenue and expense 9 month

Period end	Revenue	Research and development	Selling, general and administrative	Operating expenses	Net income
2025-09-30	$56.19M	$9.74M	$170.17M	$194.17M	-$129.97M
2024-09-30	$2.57M	$16.55M	$36.18M	$52.85M	-$41.94M
2023-09-30	$30.00K	$16.86M	$40.46M	$57.32M	-$47.20M
2022-09-30	$1.32M	$13.67M	(m)	$21.39M	-$20.25M
2021-09-30	(m)	$45.63M	(m)	$66.08M	-$66.02M
2020-09-30	(m)	$15.74M	(m)	$19.82M	-$19.86M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2025-12-31	$84.28M	(m)	$13.18M	$230.12M	$263.73M	-$80.00K	-$171.30M
2024-12-31	$89.15M	(m)	$19.58M	$71.67M	$92.23M	$288.00K	$8.00M
2023-12-31	$30.00K	$0.00	$20.27M	$47.28M	$67.55M	$0.00	-$54.37M
2022-12-31	$1.32M	(m)	$18.38M	$603.00K	$36.83M	$0.00	-$34.68M
2021-12-31	$5.51M	(m)	$20.27M	(m)	$24.96M	$0.00	-$20.24M
2020-12-31	(m)	(m)	$24.58M	(m)	$32.92M	$0.00	-$32.95M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Atea Pharmaceuticals, Inc. (AVIR)	United States	$0.414B	-2.26
RELMADA THERAPEUTICS, INC. (RLMD)	United States	$0.406B	-11.92
Opus Genetics, Inc. (IRD)	United States	$0.406B	-3.16
DiaMedica Therapeutics Inc. (DMAC)	United States	$0.423B	-10.11
Arcturus Therapeutics Holdings Inc. (ARCT)		$0.402B	-2.05
GALECTIN THERAPEUTICS INC (GALT)	United States	$0.399B	-11.06
PROTHENA CORP PUBLIC LTD CO (PRTA)	Ireland	$0.428B	-11.53
Turn Therapeutics Inc. (TTRX)	United States	$0.397B	-25.68
CYPHERPUNK TECHNOLOGIES INC. (CYPH)	United States	$0.438B	-75.63
Quoin Pharmaceuticals Ltd. (QNRX)		$0.443B	-17.85